

HOMBURGER ADVISES VECTIVBIO ON ITS FOLLOW-ON PUBLIC OFFERING AND PRIVATE PLACEMENT

Posted on 17 June 2022



Category: [Capital Markets](#)

Tags: [Andreas Müller](#), [Angela Oppliger](#), [Homburger](#), [Kevin Hubacher](#), [Kevin Müller](#), [Margrit Marti](#), [Oliver Kneubühl](#), [Slider](#), [Stefan Oesterhelt](#), [VectivBio](#)



VectivBio Holding a clinical-stage biopharmaceutical company, has announced a combined gross proceeds from public offering and private sale of USD 50 million. On one side, the company has announced the pricing of a follow-on public offering of ordinary shares in the United States, raising gross proceeds of USD 30 million. In addition to the ordinary shares sold in the public offering, VectivBio has agreed to a concurrent private placement of ordinary shares for gross proceeds of approximately USD 20 million. The closing of the private placement transaction is not contingent on any public offering. The weighted average price per ordinary share in the public offering and private placement is approximately \$5.44 per ordinary share.

The company, pioneering in novel transformational treatments for severe rare conditions, intends to use the net proceeds from the public offering and the concurrent private placement, together with its existing cash and cash equivalents, to fund clinical development and pre-commercialization activities for its lead product candidate and general corporate purposes, including general and administrative expenses and working capital.

The [Homburger](#) team includes partner **Andreas Müller** (pictured left) and lead associate **Margrit Marti** (both capital markets; corporate / m&a; pictured right), associates **Kevin Hubacher**, **Angela Oppliger** and **Oliver Kneubühl** (all corporate / m&a), and partner **Stefan Oesterhelt** and associate

Kevin Müller (both tax).